Reporting from: – 4th European Breast Cancer Conference, March 16-20, 2004, Hamburg – 6th International Symposium on Hodgkin’s Lymphoma – 16th EORTC-NCI-AACR Symposium on Molec
Reporting from:
– 4th European Breast Cancer Conference, March 16-20, 2004, Hamburg
– 6th International Symposium on Hodgkin’s Lymphoma
– 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, September 28-October 1, 2004, Geneva
– Journal of Clinical Oncology
– New England Journal of Medicine
– Lancet
– British Journal of Cancer
In this edition:
Ian Smith questions the routine use of radiotherapy for patients with breast cancer treated with lumpectomy in the light of two publications and his editorial in the New England Journal of Medicine.
The molecularly targeted drug cetuximab could be reversing irinotecan resistance in patients with metastatic colorectal cancer, according to Naureen Starling and Eric van Cutsem.
The usefulness of adjuvant chemotherapy in patients with stage II colon cancer is discussed by George Canellos and Gordon McVie following publications in the Journal of Clinical Oncology.
An analog of thalidomide shows promise for treating patients with relapsed, refractory myeloma, according to Steven Schey.
In a group of patients with hormone-refractory metastatic prostate cancer, Alison Birtle has found a non-taxane regimen to be as promising as the recent results using docetaxel.